Zobrazeno 51 - 60
of 320
pro vyhledávání: '"Michael J. Pishvaian"'
Autor:
Jonathan R. Brody, Jordan M. Winter, John M. Pascal, Charles J. Yeo, Karen E. Knudsen, Michael J. Pishvaian, Nicole Meisner-Kober, Wei Jiang, Eric Londin, Laura Scolaro, Avinoam Nevler, Joseph A. Cozzitorto, Shruti Lal, Carmella Romeo, Akshay R. Kamath, Matthew J. Schiewer, Mahsa Zarei, Saswati N. Chand
The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth and progression. Here, we show that CRISPR-Cas9–mediated silencing of the HuR locus increases the relative sensitivity o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e688631f4d8913a6df8fd435f6096086
https://doi.org/10.1158/0008-5472.c.6509622.v1
https://doi.org/10.1158/0008-5472.c.6509622.v1
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Table S1: BROCA-HR gene list Table S2: Best Response, TTP, OS in Patients with HR-DDR Defects
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2aa7244ad887ba1c96708f23ce42ce3e
https://doi.org/10.1158/1078-0432.22483595
https://doi.org/10.1158/1078-0432.22483595
Autor:
Jonathan R. Brody, Jordan M. Winter, John M. Pascal, Charles J. Yeo, Karen E. Knudsen, Michael J. Pishvaian, Nicole Meisner-Kober, Wei Jiang, Eric Londin, Laura Scolaro, Avinoam Nevler, Joseph A. Cozzitorto, Shruti Lal, Carmella Romeo, Akshay R. Kamath, Matthew J. Schiewer, Mahsa Zarei, Saswati N. Chand
HuR regulates all isoforms of PARG by binding a discrete minimal binding region (MBR) within its 3'UTR in both DDR- proficient MIA PaCa-2 and DDR- deficient Hs 766t cells. Such PARG mRNA and protein expression is also increased with other non-PARPi s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::332843cbc4b65c7ff46edcdc9626968c
https://doi.org/10.1158/0008-5472.22416714
https://doi.org/10.1158/0008-5472.22416714
Autor:
Carlos L. Arteaga, Erik S. Knudsen, Wenyi Wei, Teresa C. Dugger, David A. Riddle, Michael J. Pishvaian, Paula R. Pohlmann, Melinda E. Sanders, Paula G. Ericsson, Violeta Sánchez, Mónica Valéria Estrada, Preston D. Moore, Agnieszka K. Witkiewicz, Katherine E. Hutchinson, Kyung-Min Lee, Luigi Formisano, Joshua A. Bauer, Neil E. Bhola, Valerie M. Jansen
Supplementary Figure S1. RNAi screen to identify kinases that sensitize cells to CDK4/6 inhibition. Supplementary Figure S2. Calculation of the sensitivity index (SI) value. Supplementary Figure S3. PDK1 and CDK4/6 inhibitors are synergistic against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad87a39fc7665994129ea46a0e522f6a
https://doi.org/10.1158/0008-5472.22417598.v1
https://doi.org/10.1158/0008-5472.22417598.v1
Autor:
Jonathan R. Brody, Allan M. Jordan, Dominic I. James, Donald Ogilvie, Michael J. Pishvaian, Talia Golan, Kenneth P. Olive, Jordan M. Winter, Charles J. Yeo, Dikla Atias, Yulia Glick Gorman, Chani Stossel, Maria Raitses-Gurevich, Ian D. Waddell, Kate M. Smith, Cinthya Yabar Lowder, Christopher W. Schultz, Joseph Cozzitorto, Avinoam Nevler, AnnJosette Ramirez, Saswati N. Chand, Grace A. McCarthy, Lebaron C. Agostini, Aditi Jain
Supplementary Table 1 describes BRCA and KRAS status of PDX models and IC50 of PDDX-001 and olaparib in PDAC/PDX lines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::026a9815acebb66132a058861657f64e
https://doi.org/10.1158/0008-5472.22421172
https://doi.org/10.1158/0008-5472.22421172
Autor:
Carlos L. Arteaga, Erik S. Knudsen, Wenyi Wei, Teresa C. Dugger, David A. Riddle, Michael J. Pishvaian, Paula R. Pohlmann, Melinda E. Sanders, Paula G. Ericsson, Violeta Sánchez, Mónica Valéria Estrada, Preston D. Moore, Agnieszka K. Witkiewicz, Katherine E. Hutchinson, Kyung-Min Lee, Luigi Formisano, Joshua A. Bauer, Neil E. Bhola, Valerie M. Jansen
Supplementary Materials and Methods and Figure Legends for Supplementary Figures S1-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2af58ae1fd4d3e24d6c5e617f0e03c98
https://doi.org/10.1158/0008-5472.22417595.v1
https://doi.org/10.1158/0008-5472.22417595.v1
Autor:
John L. Marshall, Jean Viallet, Mark S. Berger, Lillian L. Siu, J.F. Deeken, Michael J. Pishvaian, David Mendelson, John Kuruvilla, Jimmy J. Hwang
Purpose: Two phase I, single-agent studies were conducted to determine the dose and regimen of obatoclax, an antagonist of all BCL-2 antiapoptotic proteins, for evaluation in phase II trials. The two studies, GX001 and GX005, evaluated the safety and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd7cac9cd54452ce63b1171daaaedfe
https://doi.org/10.1158/1078-0432.c.6519491
https://doi.org/10.1158/1078-0432.c.6519491
Autor:
Howard S. Hochster, Andrew M. Lowy, Shay Bellasea, Mai Duong, Marc R. Radke, Dana Backlund Cardin, Ignacio Garrido-Laguna, Jennifer M. Suga, Marcus S. Noel, Jordan Berlin, Michael J. Pishvaian, Florencia Jalikis, Elizabeth M. Swisher, Philip A. Philip, Katherine A. Guthrie, E. Gabriela Chiorean
Purpose:PARP inhibitors synergize with topoisomerase inhibitors, and veliparib plus modified (m) FOLFIRI (no 5-FU bolus) had preliminary activity in metastatic pancreatic cancers. This study evaluated the safety and efficacy of second-line treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29e14e2256fbd8da39e6b01f4ebec903
https://doi.org/10.1158/1078-0432.c.6531176.v1
https://doi.org/10.1158/1078-0432.c.6531176.v1
Autor:
Lillian L. Siu, Ina Rhee, Mahrukh Huseni, Jeong Kim, Maria Anderson, Tony Pourmohamad, Eric Stefanich, Shang-Chiung Chen, Deepali Rishipathak, Mario Sznol, Annemie Rutten, Alexander M. Lesokhin, Laura Q. Chow, Andres Cervantes, Wilson H. Miller, Grant A. McArthur, F. Stephen Hodi, D. Ross Camidge, Ahmad Awada, Michael Gordon, Yung-Jue Bang, Michael J. Pishvaian, Maria J. de Miguel Luken, Howard A. Burris, Tae Won Kim
Supplementary Data from First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0528c7584af822078d30d2eaa31153f3
https://doi.org/10.1158/1078-0432.22486697.v1
https://doi.org/10.1158/1078-0432.22486697.v1
Autor:
Ajay K. Gopal, Aron D. Thall, Bo Huang, Craig B. Davis, Ying Chen, Rossano Cesari, Michael J. Pishvaian, Shailender Bhatia, Ronald Levy, Toshihiko Doi, Aiwu R. He, Neil H. Segal
Supplementary Table S1. Reason for treatment discontinuation Supplementary Table S2. Select laboratory abnormalities by maximum CTCAE grade Supplementary Table S3. Pharmacokinetic parameters for single-agent utomilumab (cycle 1) Supplementary Figure
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d08d9dbb5c451b56c61fbcb212dfdf52
https://doi.org/10.1158/1078-0432.22465484
https://doi.org/10.1158/1078-0432.22465484